Consistency of findings from between-trial and within-trial comparisons, formal statistical testing verifying the absence of a subgroup effect and the similarity of baseline cardiovascular risk across different cardiovascular risk categories between individual CVOTs despite the use of seemingly different enrolment criteria suggest the benefits of the use of SGLT2i or GLP-1 RA in people with type 2 diabetes and established CVD and in those at high cardiovascular and/or kidney risk [142, 253]
This divide is largely driven by cost
ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration With the EASD
The loss: CagriSema, Novo's next-generation combination of cagrilintide and semaglutide, failed its primary endpoint in the REDEFINE 4 head-to-head trial against tirzepatide
Emily has a calming presence and immaculate bedside manner
Obesity rates in adolescents ages 12-19 have gone up significantly over the past five years, with researchers predicting even greater increases in the near future
